News and Views
Nature Chemical Biology 5, 144 - 145 (2009)
doi:10.1038/nchembio0309-144
A pulse at the heart of targeted therapy
James E Bradner1
-
James E. Bradner is at the Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA.
e-mail: james_bradner@dfci.harvard.edu
Abstract
Inhibition of growth stimulatory pathways has emerged as a major focus of targeted cancer drug development. New insights regarding potent, transient inhibition of cell signaling may challenge the dogma of medicinal chemistry and clinical trial design.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Where lies the blame for resistance?tumor or host?Nature Medicine News and Views (01 Oct 2007)
RESEARCH
Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic resultsBone Marrow Transplantation Original Article
Short-term intense Bcr?Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL + cellsLeukemia Letter
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibLeukemia Original Article
See all 27 matches for Research
